Home

University of Pennsylvania
Infectious Disease Therapeutic Clinical Trials Unit Homepage   

The University of Pennsylvania’s Infectious Disease Therapeutic Clinical Trials Unit develops and conducts clinical trials and novel therapies for HIV, COVID-19, HSV, Mpox, Ebola and other infectious diseases.

The Infectious Disease Therapeutic Clinical Trials Unit is a member of Advancing Clinical Therapeutics Globally (ACTG), the largest global HIV research network, funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH). The mission of the ACTG network is to cure HIV and reduce the burden of disease due to HIV and its complications, including tuberculosis and viral hepatitis.

The Penn Infectious Disease Therapeutic Clinical Trials Unit conducts a wide range of clinical trials for people with HIV including ground breaking research to improve the treatment of HIV, including cure research, as well as coinfections and comorbidities. As part of the federally funded ACTG, Penn’s Infectious Disease Therapeutic Clinical Trials Unit has a Community Advisory Board (CAB).  This board provides advocacy and partnership for affected communities.